

Form PTO-1390
P21961.P01U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTORNEY'S DOCKET NUMBER
P21961TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/030170

INTERNATIONAL APPLICATION NO.

PCT/IB00/01112

INTERNATIONAL FILING DATE

09 August 2000

PRIORITY DATE CLAIMED

09 August 1999

TITLE OF INVENTION

THERAPEUTIC AGENT FOR DIABETES

APPLICANT(S) FOR DO/EO/US

Shigeo TAKADA, Yasukazu NAGATO, and Masahiro MURAKAMI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☒ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. Assignee: AMATO PHARMACEUTICAL PRODUCTS, Ltd. of Kyoto, JAPAN
12. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ Figure of Drawing to be published I
18. ☒ Other items or information:
Cover Sheet and International Application as published in Japanese.
PCT/RO/101-PCT Request(in English and Japanese).
PCT/RO/102(in Japanese).
PCT/PE/A/408(in Japanese).
PCT/PE/A/409(in Japanese).
PCT/IB/301.
PCT/IB/304.
PCT/IB/306.
PCT/IB/308.
PCT/IB/332.
PCT/ISA/210(in English and Japanese).
Cover Letter under 35 U.S.C. 371 and 1.495.
Claim of Priority.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)
107030170

INTERNATIONAL APPLICATION NO.
 PCT/IB00/01112

ATTORNEY'S DOCKET NUMBER
 P21961

19. ☒ The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search report has been prepared by the EPO or JPO. \$ 890.00

International preliminary examination fee paid to USPTO (37 CFR 1.482). \$ 710.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)). \$ 740.00

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,040.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$ 100.00

CALCULATIONS	PTO USE ONLY

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	RATE
Total Claims	21 - 20 =	1	X \$18.00
Independent Claims	2 - 3 =	0	X \$84.00
Multiple dependent claim(s) (if applicable)			+ \$280.00

\$18.00	\$0.00	\$

TOTAL OF ABOVE CALCULATIONS =

\$5908.00

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

\$

SUBTOTAL =

\$908.00

Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

+

Extension of Time fee in the amount of \$

TOTAL NATIONAL FEE =

\$908.00

Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

TOTAL FEES ENCLOSED =

\$908.00

	Amount to be refunded	\$
	Charged	\$

- a. ☐ A check in the amount of \$908.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. in the amount of \$ to cover the above fees.
- c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0089.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055
 AT THE PRESENT ADDRESS OF:
 Bruce H. Bernstein
 GREENBLUM & BERNSTEIN, P.L.C.
 1941 Roland Clarke Place
 Reston, VA 20191
 (703) 716-1191



PATENT TRADEMARK OFFICE

Bruce H. Bernstein
 SIGNATURE
 Bruce H. Bernstein
 NAME
 29.027
 REGISTRATION NUMBER

P21961.A01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shigeo TAKADA et al.

Serial No : Not Yet Assigned (National Stage of PCT/IB00/01112)

Filed : Concurrently Herewith (International Filing Date August 9, 2000)

For : THERAPEUTIC AGENT FOR DIABETES

PRELIMINARY AMENDMENTCommissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Prior to calculation of the filing fees and the examination of the above-identified patent application on the merits, the Examiner is respectfully requested to amend the claims as follows:

IN THE CLAIMS

Please amend claims 3, 5, and 7 as follows (a marked-up copy of the claim amendments is provided as an attachment to this Amendment):

3. (Amended-Clean Text) The medicament according to claim 1, wherein the lactic acid which is a repeating unit in the poly lactic acid, substantially consists of L-lactic acid.

5. (Amended-Clean Text) The medicament according to claim 1 wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

7. (Amended-Clean Text) The medicament according to claim 5 wherein the reverse phase column chromatography is performed by ODS column chromatography.

Please add new claims 8 to 21 as follows:

---8. The medicament according to claim 2, wherein the lactic acid which is a repeating unit in the poly lactic acid, substantially consists of L-lactic acid.

9. The medicament according to claim 2 wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column

chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

10. The medicament according to claim 3 wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

11. The medicament according to claim 8 wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

12. The medicament according to claim 9 wherein the condensation by dehydration is performed by stepwise decompression and temperature rise under nitrogen gas atmosphere.

P21961.A01

13. The medicament according to claim 10 wherein the condensation by dehydration is performed by stepwise decompression and temperature rise under nitrogen gas atmosphere.

14. The medicament according to claim 11 wherein the condensation by dehydration is performed by stepwise decompression and temperature rise under nitrogen gas atmosphere.

15. The medicament according to claim 6 wherein the reverse phase column chromatography is performed by ODS column chromatography.

16. The medicament according to claim 9 wherein the reverse phase column chromatography is performed by ODS column chromatography.

17. The medicament according to claim 10 wherein the reverse phase column chromatography is performed by ODS column chromatography.

18. The medicament according to claim 11 wherein the reverse phase column chromatography is performed by ODS column chromatography.

P21961.A01

19. The medicament according to claim 12 wherein the reverse phase column chromatography is performed by ODS column chromatography.

20. The medicament according to claim 13 wherein the reverse phase column chromatography is performed by ODS column chromatography.


21. The medicament according to claim 14 wherein the reverse phase column chromatography is performed by ODS column chromatography.---

REMARKS

By the above amendment, claims 3, 5, and 7 have been amended and claims 8 to 21 have been added to delete multiple dependency.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Shigeo TAKADA et al.


Bruce H. Bernstein
Reg. No. 29,027 33,329

January 31, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

P21961.A01

MARKED-UP COPY OF AMENDED CLAIMS

3. (Amended) The medicament according to claim 1 [or 2], wherein the lactic acid which is a repeating unit in the poly lactic acid, substantially consists of L-lactic acid.

5. (Amended) The medicament according to claim 1 [any of claims 1 to 3] wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

7. (Amended) The medicament according to claim 5 [or 6] wherein the reverse phase column chromatography is performed by ODS column chromatography.

5/PRTS

10/030170
531 Rec'd PCT/PT 31 JAN 2002

DESCRIPTION THERAPEUTIC AGENT FOR DIABETES

TECHNICAL FIELD

The present invention relates to a medicament for prevention and/or treatment of diabetes or diabetes complications, more specifically a medicament for prevention and/or treatment of diabetes or diabetes complications which comprises, as an active ingredient, a mixture of poly lactic acids having certain condensation degree.

BACKGROUND ART

Diabetes is a metabolic disorder mainly of glucose metabolism which is based on deficient secretion of insulin or reduced sensitivity of target cells thereof, and a major characteristic of diabetes is hyperglycemia. If hyperglycemia persists for a long period, serious complications such as retinopathy, nephropathy and neuropathy arise in various organs and nerves with angiopathy as a prime factor. Therefore, it is extremely important in the treatment of diabetes to control the blood sugar level and maintain it at a normal level, and the means for this purpose has been studied for many years.

Diabetes is classified according to the types of disease into insulin dependent diabetes (IDDM; type I diabetes) and non-insulin dependent diabetes (NIDDM; type II diabetes). In the case of non-insulin dependent diabetes (type II diabetes), onset of the disease is slow and insulin treatment is not necessarily required for maintaining life, and the blood sugar level can be controlled by a combination of diet therapy, kinesitherapy and drug therapy. In drug therapy, an insulin secretion promoting agent which is one type of oral agents for reducing the blood sugar level is widely and clinically used. However, since currently available insulin secretion promoting agents promote insulin secretion independent of blood sugar level, there arise problems that onset of serious hypoglycemia arises or the blood sugar level cannot be sufficiently controlled if the dosage is inadequate, and thus such agents are not satisfactory.

Therefore, if there is provided a novel medicament which can adequately

control the blood sugar level and has little side effect, it is expected to be extremely useful for controlling the blood sugar level in diabetes patients.

DISCLOSURE OF THE INVENTION

An object of the present invention is to provide a medicament for prevention and/or treatment of diabetes or diabetes complications, which has an action of reducing the blood sugar level.

As a result of concentrated research to achieve the aforementioned object, the present inventors have found that the blood sugar level can be significantly reduced by administering a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 to diabetes-induced model rats, thereby providing the present invention. Although it has been reported in the research up to now that a mixture of cyclic and/or straight chain poly L-lactic acids having a condensation degree of 3 to 19 is useful as an antineoplastic agent (Japanese Patent Application Laying-Open (Kokai) Nos. 9-227388 and 10-130153) and also as a QOL improving agent for cancer patients (Japanese Patent Application No. 11-39894 Specification; Bulletin of Japan Society of Clinical Oncology, Vol. 33, No. 3, p. 493), the present inventors have found for the first time that it has an action of reducing the blood sugar level.

Thus, according to the first aspect of the present invention, there is provided a medicament for prevention and/or treatment of diabetes or diabetes complications which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.

According to another aspect of the present invention, there is provided a medicament for reducing the blood sugar level which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.

The medicament of the present invention may be used, in particular, for prevention and/or treatment of type II diabetes or complications thereof.

In a preferred embodiment of the present invention, the lactic acid which is a

repeating unit in the poly lactic acid, substantially consists of L-lactic acid.

In one embodiment of the present invention, the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 that is used as an active ingredient, is a fraction obtained by condensing lactic acids (preferably lactic acid substantially consisting of L-lactic acid) by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.

Condensation of lactic acids by dehydration may be performed, for example, by stepwise decompression and temperature rise under a nitrogen gas atmosphere.

Moreover, reverse phase column chromatography may be performed applying ODS column chromatography.

According to another aspect of the present invention, there is provided the use of a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 for the production of a medicament for prevention and/or treatment of diabetes or diabetes complications or a medicament for reducing the blood sugar level.

According to a further aspect of the present invention, there is provided a method for prevention and/or treatment of diabetes or diabetes complications or a method for reduction of the blood sugar level, which comprises a step of administering to mammals including humans, a therapeutically effective amount of a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a mass spectrum of the mixture of poly lactic acids obtained by Production Example 1 of the present specification.

Figure 2 is a graph showing the effect of the mixture of poly lactic acids on the fasting blood sugar level.

Figure 3 is a graph showing the effect of the mixture of poly lactic acids on

the morning blood sugar level.

Figure 4 is a graph showing the effect of the mixture of poly lactic acids on the food consumption.

Figure 5 is a graph showing the effect of the mixture of poly lactic acids on the weight increase.


THE BEST MODE FOR CARRYING OUT THE INVENTION

The embodiments and methods for carrying out the present invention are described in detail below.

In the medicament of the present invention, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is used as an active ingredient.

The term "a mixture of poly lactic acids" used in the present invention means a mixture wherein cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 are present at any ratio. That is to say, the term "mixture" does not only mean a mixture of poly lactic acids having any condensation degree ranging from 3 to 19, but is also used as a concept including a mixture of cyclic and straight chain poly lactic acids. As is described below in the present specification, "a mixture of poly lactic acids" can be obtained by condensing lactic acids by dehydration and then performing purification by a suitable method. Although the term "a mixture of poly lactic acids" is used in the present specification for the sake of convenience, this term also includes a poly lactic acid consisting of a single ingredient such as a cyclic poly lactic acid having single condensation degree or a straight chain poly lactic acid having single condensation degree.

The term "condensation degree" is used to mean the number of lactic acid unit which is repeating unit in poly lactic acids. For example, the cyclic poly lactic acid is assumed to have the following structural formula wherein n represents condensation degree ($n = 3$ to 19).



When "lactic acid" is simply referred to in the present specification, this lactic acid includes all of L-lactic acid, D-lactic acid or a mixture comprising these types of lactic acid at any ratio. Preferably in the present invention, the lactic acid substantially consists of L-lactic acid. The term "substantially" is used herein to mean that the ratio of L-lactic acid units in a mixture of poly lactic acids (number of L-lactic acid unit / number of L-lactic acid unit + number of D-lactic acid unit \times 100) is, for example, 70% or more, preferably 80% or more, more preferably 85% or more, further more preferably 90% or more, and particularly preferably 95% or more. The ratio of L-lactic acid units in a mixture of poly lactic acids depends on the ratio of L-lactic acid and D-lactic acid, which exist in lactic acids used as a starting substance.

Since a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 shows an action of suppressing a high blood sugar level in a diabetes-induced mouse, the mixture is useful as an active ingredient in a medicament for prevention and/or treatment of diabetes or diabetes complications (e.g. retinopathy, nephropathy or neuropathy).

The methods for producing a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 are not particularly limited, and the mixture of poly lactic acids can be obtained by the production methods described, for example, in Japanese Patent Application Laying-Open (Kokai) Nos. 9-227388 and 10-130153 or Japanese Patent Application No. 11-39894 (All publications cited herein are incorporated herein by reference in their entirety).

More specifically, for example, a mixture of cyclic and/or straight chain poly

lactic acids having a condensation degree of 3 to 19 can be obtained by the following method.

First, lactic acid (preferably, lactic acid substantially consisting of L-lactic acid) is condensed by dehydration under an inactive atmosphere. Examples of the inactive atmosphere include nitrogen gas and argon gas, and nitrogen gas is preferred.

Dehydration and condensation reaction is carried out at a temperature of 110°C to 210°C, preferably 130°C to 190°C under normal pressure or reduced pressure (about 1mmHg), and particularly preferably the reaction is carried out by stepwise decompression and stepwise temperature rise. A reaction period can be determined as appropriate. For example, the reaction can be carried out for 1 to 20 hours. Where stepwise decompression and stepwise temperature rise are applied, the reaction period is divided into two or more partial reaction periods, and then pressure and temperature are determined for each of the reaction periods. Where stepwise decompression is applied, pressure can be reduced, for example, from a normal pressure to 150mmHg and then to 3mmHg. Where stepwise temperature rise is applied, temperature can be raised, for example, from 145°C to 155°C and then to 185°C. Practically, the reaction can be carried out by using these conditions in combination, for example, 145°C, normal pressure, 3 hours; 145°C, 150mmHg, 3 hours; 155°C, 3mmHg, 3 hours; and 185°C, 3mmHg, 1.5 hours.

Subsequently, ethanol and methanol are added to the reaction mixture obtained by the dehydration and condensation reaction, and the mixture is filtered. The obtained filtrate is dried to obtain ethanol and methanol-soluble fractions. The term "ethanol and methanol-soluble fractions" is used in the present specification to mean fractions soluble in a mixed solution of ethanol and methanol. In order to obtain ethanol and methanol-soluble fractions, a reaction mixture obtained by dehydration and condensation reaction is mixed with ethanol and methanol, where the ratio of ethanol and methanol can be determined as appropriate. For example, the ratio is ethanol:methanol = 1 : 9. The order and method for adding ethanol and methanol to a reaction mixture are not limited, and may be selected as appropriate. For example,

ethanol may be added at first to the reaction mixture obtained by the dehydration and condensation reaction, and then methanol may be added thereto.

The thus obtained ethanol and methanol-soluble fractions can be subjected to reverse phase column chromatography, especially to chromatography where an octadecylsilane (ODS) column is used. First, fractions eluted with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 are removed, and then fractions eluted with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3, preferably 99 weight % or more acetonitrile aqueous solution are collected so as to obtain a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.

The obtained mixture of cyclic and/or straight chain poly lactic acids is neutralized with an alkaline substance such as sodium hydroxide, and is dried under reduced pressure, and then according to standard techniques, the mixture can be formulated in a desired forms as mentioned below.

The dosage form of the medicament of the present invention is not particularly limited, and any form suitable for the purpose of treatment or prevention can be selected from dosage forms for oral or parenteral administration. Examples of dosage forms suitable for oral administration include a tablet, a capsule, a powder, a granule, a parvule, a syrup, a solution, an emulsion, a suspension, a chewable tablet, and the like. Examples of dosage forms suitable for parenteral administration include, but are not limited to, an injection (e.g. a subcutaneous, intramuscular or intravenous injection, and the like), a drop, an inhalant, a nebula, a suppository, an agent for percutaneous absorption in the form of a gel, ointment or the like, an agent for mucomembranous absorption, and an agent for percutaneous absorption in the form of an adhesive skin patch, tape or the like.

Aqueous formulations suitable for oral administration such as a solution, emulsion or syrup can be produced using water; sugars such as sucrose, sorbit or fructose; glycols such as polyethylene glycol or propylene glycol; oils such as sesame oil, olive oil or soybean oil; antiseptics such as p-hydroxybenzoate; and flavors such as strawberry flavor and peppermint. In order to produce solid formulations such as

capsule, tablet, powder or granule, there can be used an excipient such as lactose, glucose, sucrose or mannite; a disintegrator such as starch or sodium alginate; a lubricant such as magnesium stearate or talc; a binder such as polyvinyl alcohol, hydroxypropylcellulose or gelatin; a surfactant such as fatty acid ester; and a plasticizer such as glycerine, and the like.

Formulations for an injection or drop that are suitable for parenteral administration preferably comprise, as an active ingredient, the above substance in a dissolved or suspended state in a sterilized aqueous medium which is isotonic to the recipient's blood. For example, in the case of an infection, a solution can be prepared using an aqueous medium consisting of a saline solution, a glucose solution or a mixture of a saline solution and a glucose solution. In the case of a formulation for intestinal administration, it can be prepared using carriers such as a theobroma oil, hydrogenated lipids or hydrogenated carboxylic acid, and can be provided as a suppository. In order to produce a nebula, the above substance as an active ingredient may be dispersed as microparticles, and a carrier which does not irritate the recipient's cavitas oris and respiratory tract mucosa and which facilitates absorption of the active ingredient can be used. Specific examples of carriers include lactose, glycerine, and the like. Formulations having a form such as aerosol or dry powder may be prepared depending on the properties of the substance of an active ingredient and the carrier. One or two or more auxiliary ingredients selected from glycols, oils, flavors, an antiseptic, an excipient, a disintegrator, a lubricant, a binder, a surfactant, a plasticizer and the like may be added to these formulations for parenteral administration.

The dose and dosage frequency of the medicament of the present invention is determined as appropriate, depending on various factors such as the type and seriousness of the disease, dosage form, age or body weight of a patient, or the presence or absence of complications. Generally, the dose of an active ingredient per day is 20 to 2,000mg/kg, preferably 20 to 200mg/kg, and more preferably 50 to 150mg/kg. It is preferred that the above dose of medicament is dividedly applied about once to 4 times per day, more preferably about twice to 4 times per day.

The medicament of the present invention can be administered to any mammal including humans, preferably being administered to humans.

The medicament of the present invention can be used for prevention and/or treatment of diabetes or diabetes complications. Diabetes is one disease, which is based on a disorder of glucose metabolism, a major characteristic of diabetes being hyperglycemia. Diabetes can be treated by reducing the blood sugar level of a diabetes patient using the medicament of the present invention. Also, diabetes can be prevented by controlling the blood sugar level of a diabetes suspected patient using the medicament of the present invention. It is known that, since hyperglycemia persists for a long period in a diabetes patient, complications such as retinopathy, nephropathy and neuropathy develop with angiopathy as a prime factor. These diabetes complications can also be prevented and/or treated by controlling the blood sugar level of a diabetes patient using the medicament of the present invention.

Moreover, the medicament of the present invention cannot only be used for prevention and/or treatment of diabetes or complications thereof, but also can broadly be used to reduce the blood sugar level. Where hyperglycemia is clinically present, diabetes is suspected, but hyperglycemia may sometimes occur due to various diseases other than diabetes. For example, hyperglycemia occurs due to various factors such as organic disorder of pancreatic tissues, chronic hepatopathy, endocrinopathy, symptom of brain hypertension, adiposis, hyperphagia, crapula of alcohol, postgastrectomy nutritional hyperglycemia, fibrile disease, carbon monoxide poisoning, increase of blood sugar due to drugs, and the like. The medicament of the present invention may be used to reduce these high level of blood sugar.

The present invention is further described in the following examples, but the examples are not intended to limit the scope of the present invention.

EXAMPLES

Production Example 1: Production of a mixture of poly lactic acids

500 ml of L-lactic acid (to which D-lactic acid is also mixed) was placed into

a separable flask in a mantle heater. 300ml/min of nitrogen gas was flowed therein while stirring. Accumulated water was introduced into a flask equipped with a reflux condenser via a warmed descending type connecting tube, while heating at 145°C for 3 hours. Furthermore, after pressure was reduced to 150mmHg and heated at the same temperature for 3 hours, the mixture was heated at 155°C for 3 hours under a reduced pressure of 3mmHg, and then at 185°C for 1.5 hours under a reduced pressure of 3mmHg to obtain poly lactic acids as a reaction product.

The obtained poly lactic acids were kept at 100°C, and 100ml of ethanol and 400ml of methanol were separately added thereto, and then the mixture was allowed to be cooled. This mixture was added to 500ml of methanol, and the mixture was well stirred and left to stand. Then, the mixture was filtrated for purification. The filtrate was subjected to vacuum drying and then dissolved in acetonitrile to obtain 200ml (stock solution) in total.

The stock solution was placed to a reverse phase ODS column (TSK gel ODS-80 TM) which was previously equilibrated, and was stepwise eluted with 30%, 50% and 100% acetonitrile (pH2.0) each containing 0.01M hydrochloric acid to obtain poly lactic acids (condensation degree of 3 to 19) as an acetonitrile 100% elution fraction. The mass spectrum of the obtained substance is shown in Figure 1. As is clear from the regular fragment ion peaks in Figure 1, the obtained mixture of poly lactic acids mainly comprises cyclic condensate, and a small amount of linear condensate is contained therein.

Test Example 1: Evaluation of action of a mixture of poly lactic acids using diabetes-induced mice

(Method)

Diabetes-induced mice (diabetes mice; C57BL/KsJ-db/db Jcl) were used as test animals. Each of these mice is a homozygote for a recessive gene, db, which exists on the 4th chromosome, and is a diabetes model mouse which rapidly develops type II diabetes by edacity.

These mice (6-week-old female mice obtained from CLEA Japan, Inc.) were divided into two groups: (1) a CE2 group (12 mice), which were fed with standard solid food CE2 (obtained from CLEA Japan, Inc.) and (2) a CPL group (12 mice), which were fed with standard solid food CE2 containing 1 weight % (where a fraction obtained by chromatography is used as is, and the concentration thereof is 1 weight %) of a mixture of poly lactic acids (also referred as to CPL), and then the mice in these groups were fed for 35 days. As a control group, heterozygotes (4 mice; C57BL/KsJ-db/-Jcl) for a recessive gene, db, were fed with standard solid food CE2.

Over the whole period of feeding, fasting blood sugar level, morning blood sugar level, food consumption per day, and body weight were measured.

(Results)

The results obtained from measurement of fasting blood sugar level are shown in Table 1 and Figure 2, and the results obtained from measurement of morning blood sugar level, food consumption per day and body weight are shown in Figures 3 to 5.

Table 1: Results of measurement of fasting blood sugar level (the unit of values in the table is mg/dl)

Feeding period (days)	Control group (db/-)	Experiment group (db/db)	
		Standard solid food group	CPL-containing food group
2	77.5±10.4	76.2±16.6	81.6±16.6
7		143.0±18.6	97.3±17.7
12			134.4±19.3
13		192.8±58.5	
18	69.2±11.2		
19			142.7±26.7
20		203.6±44.0	
24	98.0±11.0		
26			173.5±37.8
27			203.4±45.2
28	84.9±14.2	302.7±75.3	
31			
33			209.0±46.1
35		300.9±53.5	

As is clear from Table 1. and Figure 2, the fasting blood sugar level of mice in the CE2 group increased as they grew, and reached 300mg/dl on the 28th day after initiation of feeding. In contrast, the fasting blood sugar level of the CPL group was remarkably lower than that of the CE2 group over the whole feeding period. Especially, the fasting blood sugar level on the 27th day after initiation of feeding was about 203mg/dl on average, and this value was about 67% of the value of CE2 group on the 28th day. From these results, it was shown that fasting blood sugar level was significantly reduced by providing a feed containing 1% mixture of poly lactic acids.

Especially, the diabetes model mice used in this test are a model where the blood sugar level is not only difficult to be controlled by diet therapy or kinesitherapy, but is also difficult to be controlled even by administration of insulin. It is a surprising result that the fasting blood sugar level of such a mouse can be reduced to about 67% of a control by providing a feed containing 1% mixture of poly lactic acids. These results

suggest the possibility that the blood sugar level of diabetes patients can be controlled by administration of a mixture of poly lactic acids in combination with diet therapy and kinesitherapy.

Moreover, as shown in Figure 3, there was no significant difference between the CE2 group and the CPL group in respect of morning blood sugar level, and both groups showed similar values.

Furthermore, as shown in Figure 4, the daily average food consumption of control mice heterozygously having a db gene (C57BL/KsJ-db/-Jcl) was about 4g, whereas the daily average food consumption of diabetes-induced mice in both CE2 group and CPL group rapidly increased as they grew and reached about 7.5g on the 29th day after initiation of feeding. There was no significant difference between the daily average food consumption of the CE group and that of the CPL group.

Still further, as shown in Figure 5, in respect of weight increase of growing mice, there was no significant difference between the CE group and the CPL group, and the body weight significantly increased in both groups and reached about 43g on average on the 29th day after initiation of feeding. In contrast, weight increase of control mice (C57BL/KsJ-db/-Jcl) was more moderate than mice in both the CE and CPL groups, and the average body weight on the 31st day after initiation of feeding was about 24g.

INDUSTRIAL APPLICABILITY

The medicament of the present invention has an action of reducing the blood sugar level and is useful especially for prevention and/or treatment of diabetes or diabetes complications. Moreover, since the mixture of poly lactic acids which is used as an active ingredient in the present invention is a low condensed form of lactic acid derived from a biological ingredient, it has a high biocompatibility and has low side effects.

CLAIMS

1. A medicament for prevention and/or treatment of diabetes or diabetes complications which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.
2. A medicament for reducing the blood sugar level which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.
3. The medicament according to claim 1 or 2, wherein the lactic acid which is a repeating unit in the poly lactic acid, substantially consists of L-lactic acid.
4. The medicament according to claim 1 wherein the diabetes is type II diabetes.
5. The medicament according to any of claims 1 to 3 wherein the mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19 is a fraction obtained by condensing lactic acids by dehydration under an inactive atmosphere, subjecting the ethanol- or methanol-soluble fraction of the obtained reaction solution to reverse phase column chromatography, and eluting with 25 to 50 weight % acetonitrile aqueous solution of pH 2 to 3 and then with 90 weight % or more acetonitrile aqueous solution of pH 2 to 3.
6. The medicament according to claim 5 wherein the condensation by dehydration is performed by stepwise decompression and temperature rise under nitrogen gas atmosphere.
7. The medicament according to claim 5 or 6 wherein the reverse phase column chromatography is performed by ODS column chromatography.

ABSTRACT

The object of the present invention is to provide a medicament for prevention and/or treatment of diabetes or diabetes complications, which has an action of reducing the blood sugar level. The present invention provides a medicament for prevention and/or treatment of diabetes or diabetes complications which comprises, as an active ingredient, a mixture of cyclic and/or straight chain poly lactic acids having a condensation degree of 3 to 19.

Fig. 1




Fig.1: Mass

Fig. 2




Fig. 3

Effect of CPL on the morning blood sugar level




Fig. 4

Fig.4:

Effect of CPL on the food consumption





Fig. 5

Fig.5:

Effect of CPL on the weight increase



Declaration and Power of Attorney for Utility or Design Patent Application

特許出願宣言書

Japanese Language Declaration

私は、下欄に氏名を記載した発明者として、以下のとおり宣言する：

私の住所、郵便の宛先および国籍は、下欄に氏名に続いて記載したとおりであり、

名称の発明に関し、請求の範囲に記載した特許を求める主題の本来の、最初にして唯一の発明者である（一人の氏名のみが下欄に記載されている場合）か、もしくは本来の、最初にして共同の発明者である（複数の氏名が下欄に記載されている場合）と信じ、

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Therapeutic Agent For Diabetes

上記発明の明細書（下記の欄で x 印がついていない場合は、本書に添付）は、

☒ 年 月 日に提出され、米国出願番号

とし、（該当する場合）

年 月 日に訂正されました。又は、

特許協定条約国際出願番号 とし、

（該当する場合）年 月 日に訂正されました。

私は、前記のとおり補正した請求の範囲を含む前記明細書の内容を検討し、理解したことを陳述する。

私は、連邦規則法典第 37 編第 1 条 56 項に定義されているとおり、特許資格の有無について重要な情報を開示すべき義務があることを認めます。

the specification of which is attached hereto unless the following box is checked:

☒ was filed on 09/Aug/00 as United States Application Number 10/030,170 and was amended on 31/Jan/02 (if applicable) or,

PCT International Application Number PCT/B00/01112 and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority under Title 35, United States Code §119(a-d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below. I have also identified below, by checking the "No" box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

Prior foreign applications

先の外国出願

11-224683	Japan	09/Aug/99
(Number)	(Country)	(Day/Month/Year Filed)
(番号)	(国名)	(出願の年月日)

(Number)	(Country)	(Day/Month/Year Filed)
(番号)	(国名)	(出願の年月日)

Priority claimed
優先権の主張

<input checked="" type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし

<input type="checkbox"/>	<input type="checkbox"/>
Yes	No
あり	なし

☐ その他の外国特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional foreign application numbers are listed as supplemental priority sheet attached hereto.

Japanese Language Utility or Design Patent Application Declaration

私は、合衆国法典第 35 部第 119 条 (e) 項に基づく、下記の合衆国仮特許出願の利益を主張する。

I hereby claim the benefit under Title 35, United States Code §119 (e) of any United States provisional application(s) listed below.

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

☐ その他の合衆国仮特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

私は、合衆国法典第 35 部第 120 条に基づく下記の合衆国特許出願又は第 365 条 (c) 項に基づく合衆国を指名した PCT 国際出願の利益を主張し、本願の請求の範囲各項に記載の主題が合衆国法典第 35 部第 112 条第 1 項規定の態様で、先の合衆国特許出願又は PCT 国際出願に開示されていない限度において、先の出願の出願日と本願の国内出願日又は PCT 国際出願日の間に有効となった連邦特許法典第 37 部第 1 章第 56 条に記載の特許要件に所要の情報を開示すべき義務を有することを認める。

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or §365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.



(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(現況) (Status)
(特許済み、係属中 放棄済み) (patented, pending, abandoned)

(Application No.)
(出願番号)

(Day/Month/Year Filed)
(出願の年月日)

(現況) (Status)
(特許済み、係属中 放棄済み) (patented, pending, abandoned)

☐ その他の合衆国又は国際特許出願番号は別紙の追補優先権欄にて記載する。

☐ Additional U.S. or international application numbers are listed on a supplemental priority sheet attached hereto.

私は、ここに自己の知識に基づいて行った陳述が全て真実であり、自己の有する情報および信ずるところに従って行った陳述が真実であると信じ、さらに故意に虚偽の陳述等を行った場合、合衆国法典第 18 部第 1001 条により、罰金もしくは禁に処せられるか、またはこれらの刑が併科され、またかかる故意による虚偽による陳述が本願ないし本願に対して付与される特許の有効性を損うことがあることを認識して、以上の陳述を行ったことを宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

私、下記署名者は、ここに記載の米国弁護士または代理人に本出願に関し特許商標庁にて取られるいかなる行為に関して、同米国外弁護士又は代理人が私に直接連絡なしに私の外国弁護士或いは法人代表者からの指示を受け取り、それに従うようここに委任する。この指示を出す者が変更の場合には、ここに記載の米国弁護士又は代理人にその旨通知される。

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from either his foreign patent agent or corporate representative, if any, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

Japanese Language Utility or Design Patent Application Declaration

委任状: 私は、下記発明者として、下記に明記された顧客番号を伴う以下の弁護士又は、代理人をここに選任し、本願の手続きを遂行すること並びにこれに関する一切の行為を特許商標庁に対して行うことを委任する。そして全ての通信はこの顧客番号宛に発送される。

顧客番号 7055

現在委任された弁護士は下記の通りである。

Neil F. Greenblum Reg. No. 28,394
 Bruce H. Bernstein Reg. No. 29,027
 James L. Rowland Reg. No. 32,674
 Arnold Turk Reg. No. 33,094

POWER OF ATTORNEY: As a named inventor, I hereby appoint the attorney(s) and/or agent(s) associated with the Customer Number provided below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

CUSTOMER NUMBER 7055

The appointed attorneys presently include:

Stephen M. Roylance Reg. No. 31,296
 William E. Lyddane Reg. No. 41,568
 William Pieprz Reg. No. 33,630
 Leslie J. Paperner Reg. No. 33,329

Address: **GREENBLUM & BERNSTEIN, P.L.C.**
 1941 Roland Clarke Place
 Reston, VA 20191

直接電話連絡先:

Direct Telephone Calls to:

GREENBLUM & BERNSTEIN, P.L.C.
 (703) 716-1191

唯一のまたは第一の発明者の氏名 100		Full name of sole or first inventor <u>Shigeo TAKADA</u>	
同発明者の署名 高田 繁生	日付	Inventor's signature <u>Shigeo Takada</u>	Date April 17, 2002
住所		Residence <u>Kanagawa, Japan JPX</u>	
国籍		Citizenship Japan	
郵便の宛先		Post Office Address 517-12, Higashitomioka, Isehara-shi, Kanagawa 259-1112 Japan	
第二の共同発明者の氏名 (該当する場合) 200		Full name of second joint inventor, if any <u>Yasukazu NAGATO</u>	
同第二共同発明者の署名 長戸 康和	日付	Second Inventor's signature <u>Yasukazu Nagato</u>	Date April 17, 2002
住所		Residence <u>Kanagawa, Japan JPX</u>	
国籍		Citizenship Japan	
郵便の宛先		Post Office Address 2-20-12, Morinosato, Atsugi-shi, Kanagawa 243-0122 Japan	

(第三またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Utility or Design Patent Application Declaration

第三の共同発明者の氏名 (該当する場合)	300	Full name of third joint inventor, if any	
共同発明者の署名	村上正裕	Third inventor's signature	Masahiro MURAKAMI
住所		Residence	Osaka, Japan JPK
国籍		Citizenship	Japan
郵便の宛先		Post Office Address	3-17-6, Kirennishi, Hirano-ku, Osaka-shi, Osaka 547-0026 Japan
第四の共同発明者の氏名 (該当する場合)		Full name of fourth joint inventor, if any	
共同発明者の署名		Fourth inventor's signature	
住所		Residence	
国籍		Citizenship	
郵便の宛先		Post Office Address	
第五の共同発明者の氏名 (該当する場合)		Full name of fifth joint inventor, if any	
共同発明者の署名		Fifth inventor's signature	
住所		Residence	
国籍		Citizenship	
郵便の宛先		Post Office Address	
第六の共同発明者の氏名 (該当する場合)		Full name of sixth joint inventor, if any	
共同発明者の署名		Sixth inventor's signature	
住所		Residence	
国籍		Citizenship	
郵便の宛先		Post Office Address	

(それ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for subsequent joint inventors.)